Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Chiesa

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Blood Advances|November 15, 2021
Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophyRobert Chiesa, Jaap Jan Boelens, Christine N Duncan, et al.
Science Translational Medicine|January 27, 2017
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cellsWaseem Qasim, Hong Zhan, Sujith Samarasinghe, et al.
Clinical Pharmacology and Therapeutics|November 9, 2019
Proposed Therapeutic Range of Treosulfan in Reduced Toxicity Pediatric Allogeneic Hematopoietic Stem Cell Transplant Conditioning: Results From a Prospective TrialRobert Chiesa, Joseph F Standing, Robert Winter, et al.
Blood Advances|June 4, 2020
New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCTReem Elfeky, Giovanna Lucchini, Su-Han Lum, et al.
Blood Advances|April 6, 2018
Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritisJuliana M F Silva, Fani Ladomenou, Ben Carpenter, et al.
Journal of Clinical Immunology|April 16, 2025
Safety and Diagnostic Utility of Brain Biopsy and Metagenomics in Decision-Making for Patients with Inborn Errors of Immunity (IEI) and Unexplained Neurological ManifestationsJesmeen Maimaris, Julia Payne, Adriel Roa-Bautista, et al.
Blood Cancer Journal|April 15, 2024
Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access schemeMacarena Oporto Espuelas, Saskia Burridge, Amy A Kirkwood, et al.
Transplantation and Cellular Therapy|January 22, 2022
Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell TransplantationTim Bognàr, Imke H Bartelink, Toine C G Egberts, et al.
Nature Medicine|October 13, 2021
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trialShaun Cordoba, Shimobi Onuoha, Simon Thomas, et al.
The Lancet. Haematology|October 18, 2016
Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysisImke H Bartelink, Arief Lalmohamed, Elisabeth M L van Reij, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Blood Advances|November 15, 2021
Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophyRobert Chiesa, Jaap Jan Boelens, Christine N Duncan, et al.
Science Translational Medicine|January 27, 2017
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cellsWaseem Qasim, Hong Zhan, Sujith Samarasinghe, et al.
Clinical Pharmacology and Therapeutics|November 9, 2019
Proposed Therapeutic Range of Treosulfan in Reduced Toxicity Pediatric Allogeneic Hematopoietic Stem Cell Transplant Conditioning: Results From a Prospective TrialRobert Chiesa, Joseph F Standing, Robert Winter, et al.
Blood Advances|June 4, 2020
New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCTReem Elfeky, Giovanna Lucchini, Su-Han Lum, et al.
Blood Advances|April 6, 2018
Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritisJuliana M F Silva, Fani Ladomenou, Ben Carpenter, et al.
Journal of Clinical Immunology|April 16, 2025
Safety and Diagnostic Utility of Brain Biopsy and Metagenomics in Decision-Making for Patients with Inborn Errors of Immunity (IEI) and Unexplained Neurological ManifestationsJesmeen Maimaris, Julia Payne, Adriel Roa-Bautista, et al.
Blood Cancer Journal|April 15, 2024
Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access schemeMacarena Oporto Espuelas, Saskia Burridge, Amy A Kirkwood, et al.
Transplantation and Cellular Therapy|January 22, 2022
Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell TransplantationTim Bognàr, Imke H Bartelink, Toine C G Egberts, et al.
Nature Medicine|October 13, 2021
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trialShaun Cordoba, Shimobi Onuoha, Simon Thomas, et al.
The Lancet. Haematology|October 18, 2016
Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysisImke H Bartelink, Arief Lalmohamed, Elisabeth M L van Reij, et al.
Pageof 7